Phase I Evaluation of STA-1474, a Prodrug of the Novel HSP90 Inhibitor Ganetespib, in Dogs with Spontaneous Cancer

Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition

(2015)   Oncotarget

Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib

(2015) Nickolay Neznanov et al.   Oncotarget

An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors

(2010) Naveen Dakappagari et al.   BIOMARKERS

Cytoprotective Mitochondrial Chaperone TRAP-1 As a Novel Molecular Target in Localized and Metastatic Prostate Cancer

(2009) Irwin Leav et al.   AMERICAN JOURNAL OF PATHOLOGY

Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression

(2009) Melissa Paoloni et al.   BMC GENOMICS

Tanespimycin: the opportunities and challenges of targeting heat shock protein 90

(2009) Charles Erlichman   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Expression of Hsp90 chaperome proteins in human tumor tissue

(2009) Christina L. McDowell et al.   INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines

(2009) Jennifer K. McCleese et al.   INTERNATIONAL JOURNAL OF CANCER

Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90

(2009) Byoung Heon Kang et al.   JOURNAL OF CLINICAL INVESTIGATION

The Hsp90 molecular chaperone: an open and shut case for treatment

(2008) Laurence H. Pearl et al.   BIOCHEMICAL JOURNAL

Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling

(2008) Laila Al Shaer et al.   BRITISH JOURNAL OF HAEMATOLOGY

Dual Targeting of HSC70 and HSP72 Inhibits HSP90 Function and Induces Tumor-Specific Apoptosis

(2008) Marissa V. Powers et al.   CANCER CELL

Silencing of HSP90 Cochaperone AHA1 Expression Decreases Client Protein Activation and Increases Cellular Sensitivity to the HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin

(2008) J. L. Holmes et al.   CANCER RESEARCH

The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors

(2008) Tzu-Yin Lin et al.   EXPERIMENTAL HEMATOLOGY

The Hsp90 Chaperone Machinery

(2008) Sebastian Karl Wandinger et al.   JOURNAL OF BIOLOGICAL CHEMISTRY